ArticleInternal and emergency medicine2026
Venous thromboembolism in heart failure: incidence, phenotype-specific risk, and predictors in a large real-world cohort.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVenous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a clinically important complication in patients with heart failure. Despite its relevance to internal and emergency medicine practice, contemporary real-world data examining venous thromboembolism across heart failure phenotypes remain limited.
objectiveTo determine the incidence of venous thromboembolism among adults with newly diagnosed heart failure and to identify independent clinical and laboratory predictors.
methodsThis retrospective cohort study included adults diagnosed with heart failure at a tertiary medical center between 2017 and 2024. Heart failure was categorized into reduced, preserved, mildly reduced, and improved ejection fraction phenotypes. Patients receiving chronic anticoagulation or with major prothrombotic disorders were excluded. Incident venous thromboembolism events occurring in both inpatient and outpatient settings were identified during longitudinal follow-up after heart failure diagnosis. Predictors were evaluated using multivariable logistic regression and Cox proportional hazards modeling.
resultsAmong 4,211 patients followed for a median of 6.2 years (IQR: 4.6-7.5 years), 256 (6.1%) developed venous thromboembolism. Crude incidence varied by phenotype, with higher rates observed in preserved ejection fraction (7.4%; 142/1,930) than in reduced ejection fraction (4.6%; 74/1,618). However, heart failure phenotype was not independently associated with venous thromboembolism after multivariable adjustment. Patients with venous thromboembolism were older and had lower serum albumin, lower hemoglobin, more impaired kidney function, and a higher prevalence of chronic obstructive pulmonary disease. Cardiovascular survival analysis demonstrated no significant difference between venous thromboembolism and non-venous thromboembolism groups in either unadjusted (log-rank p = 0.52) or adjusted models (HR: 0.76, 95% CI: 0.30-1.93, p = 0.57).
conclusionsVenous thromboembolism is a frequent and clinically significant complication in patients with heart failure. After adjustment, venous thromboembolism risk was driven by patient-level clinical and laboratory factors rather than heart failure phenotype. These findings support vigilant monitoring and individualized risk stratification in internal medicine and emergency care settings.
Indexed as
Identifiers
41724908What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.